[ 1 ] Wei PF. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Chin Med J 2020;133(9):1087–95. link1

[ 2 ] Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Edwards KM, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis 2020;ciaa478.

[ 3 ] Zhou L, Wang XN, Liu XK, Fei X, Liu L, Liu ZL, et al. Case report of Xuanfei Baidu decoction for curing severe cases of COVID-2019. Tianjin J Tradit Chin Med 2021;38(5):556–9. Chinese. link1

[ 4 ] Xiong WZ, Wang G, Du J, Ai W. Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with conventional drug in treating COVID-19: a pilot randomized clinical trial. Integr Med Res 2020;9(3):100489. link1

[ 5 ] Leung EH, Pan HD, Huang YF, Fan XX, Wang WY, He F, et al. The scientific foundation of Chinese herbal medicine against COVID-19. Engineering 2020;6 (10):1099–107. link1

[ 6 ] Shi N, Guo L, Liu B, Bian Y, Chen R, Chen S, et al. Efficacy and safety of Chinese herbal medicine versus lopinavir–ritonavir in adult patients with coronavirus disease 2019: a non-randomized controlled trial. Phytomedicine 2021;81:153367. link1

[ 7 ] Wang Y, Lu C, Li H, Qi W, Ruan L, Bian Y, et al. Efficacy and safety assessment of severe COVID-19 patients with Chinese medicine: a retrospective case series study at early stage of the COVID-19 epidemic in Wuhan. China. J Ethnopharmacol 2021;277:113888. link1

[ 8 ] Ma Q, Qiu M, Zhou H, Chen J, Yang X, Deng Z, et al. The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical corona virus disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2. Pharmacol Res 2020;160:105073. link1

[ 9 ] Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8(4):420–2. link1

[10] Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015;1282:1–23. link1

[11] Malik YA. Properties of coronavirus and SARS-CoV-2. Malays J Pathol 2020;42 (1):3–11. link1

[12] Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J 2019;16(1):69. link1

[13] Yin W, Mao C, Luan X, Shen DD, Shen Q, Su H, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 2020;368(6498):1499–504. link1

[14] Tahir ul Qamar M, Alqahtani SM, Alamri MA, Chen LL. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal 2020;10(4):313–9. link1

[15] Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020;14 (2):185–92. link1

[16] Li Y, Zhou W, Yang Li, You R. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. Pharmacol Res 2020;157:104833. link1

[17] Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020;12(4):372. link1

[18] Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol 2020;251(3):228–48. link1

[19] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus. Lancet 2020;395(10223):497–506. link1

[20] Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 2020;17 (5):533–5. link1

[21] Ni Y, Alu A, Lei H, Wang Y, Wu M, Wei X. Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. Mol Biomed 2021;2(1):1. link1

[22] Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, et al. Cytokine storm in COVID-19-immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM consortium position paper. Front Immunol 2020;11:1648. link1

[23] Rabaan AA, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YS, et al. SARS-CoV2, SARS-CoV, and MERS-COV: a comparative overview. Infez Med 2020;28 (2):174–84. link1

[24] Mackman N, Antoniak S, Wolberg AS, Kasthuri R, Key NS. Coagulation abnormalities and thrombosis in patients infected with SARS-CoV-2 and other pandemic viruses. Arterioscler Thromb Vasc Biol 2020;40(9):2033–44. link1

[25] Reinke LM, Spiegel M, Plegge T, Hartleib A, Nehlmeier I, Gierer S, et al. Different residues in the SARS-CoV spike protein determine cleavage and activation by the host cell protease TMPRSS2. PLoS ONE 2017;12(6): e0179177. link1

[26] Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Author correction: characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune crossreactivity with SARS-CoV. Nat Commun 2021;12(1):2144. link1

[27] Raj VS, Mou H, Smits SL, Dekkers DH, Müller MA, Dijkman R, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirusEMC. Nature 2013;495(7440):251–4. link1

[28] Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003;82(2):53–73. link1

[29] Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005;11(8):875–9. link1

[30] Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. CryoEM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367(6483):1260–3. link1

[31] Mohd HA, Memish ZA, Alfaraj SH, McClish D, Altuwaijri T, Alanazi MS, et al. Predictors of MERS-CoV infection: a large case control study of patients presenting with ILI at a MERS-CoV referral hospital in Saudi Arabia. Travel Med Infect Dis 2016;14(5):464–70. link1

[32] Liu Q, Wang RS, Qu GQ, Wang YY, Liu P, Zhu YZ, et al. Gross examination report of a COVID-19 death autopsy. J Forensic Med 2020;36(1):21–3. Chinese. link1

[33] Tian S, Xiong Y, Liu H, Niu Li, Guo J, Liao M, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol 2020;33(6):1007–14. link1

[34] Gong S. Changes of the temporal-spatial distribution of epidemic disasters in 770BC-AD1911 China. Acta Geogr Sin 2003;58(6):870–8. link1

[35] Chen S, Zhou Z. On the strategy and therapy of TCM diagnosis and treatment to COVID-19. Jiangsu J Tradit Chin Med 2020;52(4):34–8. Chinese. link1

[36] Zheng W, Zhang J, Yang FW, Huang M, Miao Q, Qi WS, et al. Treatment of coronavirus disease 2019 (COVID-19) from perspective of dampness-toxicity plagues. J Tradit Chin Med 2020;61(22):1020–8. link1

[37] Rodríguez-Morales AJ, MacGregor K, Kanagarajah S, Patel D, Schlagenhauf P. Going global—travel and the 2019 novel coronavirus. Travel Med Infect Dis 2020;33:101578. link1

[38] Wang H, Song HX, Wang DF, Ma XR, Zou DX, Miao JX, et al. Potential mechanism of Xuanfei Baidu formula in treating new coronavirus pneumonia on network pharmacology and molecular docking. J Hainan Med Coll 2020;26 (18):1361–72. link1

[39] Wang Y, Li X, Zhang JH, Xue R, Qian JY, Zhang XH, et al. Mechanism of Xuanfei Baidu tang in treatment of COVID-19 based on network pharmacology. China J Clin Mater Med 2020;45(10):2249–56. Chinese. link1

[40] Pan HD, Yao XJ, Wang WY, Lau HY, Liu L. Network pharmacological approach for elucidating the mechanisms of traditional Chinese medicine in treating COVID-19 patients. Pharmacol Res 2020;159:105043. link1

[41] Zhu YW, Yan XF, Ye TJ, Hu J, Wang XL, Qiu FJ, et al. Analyzing the potential therapeutic mechanism of Huashi Baidu decoction on severe COVID-19 through integrating network pharmacological methods. J Tradit Complement Med 2021;11(2):180–7. link1

[42] Tao Q, Du J, Li X, Zeng J, Tan B, Xu J, et al. Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19. Drug Dev Ind Pharm 2020;46 (8):1345–53. link1

[43] Ren Y, Yin ZH, Dai JX, Yang Z, Ye BB, Ma YS, et al. Evidence-based complementary and alternative medicine exploring active components and mechanism of Jinhua Qinggan granules in treatment of COVID-19 based on virus–host interaction. Nat Prod Commun 2020;15(9):1934578X2094721. link1

[44] Zhang Y, Yao Y, Yang Y, Wu H. Investigation of anti-SARS, MERS, and COVID19 effect of Jinhua Qinggan granules based on a network pharmacology and molecular docking approach. Nat Prod Commun 2021;16(5): 1934578X2110206. link1

[45] Drexler JF, Gloza-Rausch F, Glende J, Corman VM, Muth D, Goettsche M, et al. Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences. J Virol 2010;84 (21):11336–49. link1

[46] Khaerunnisa S, Aminah NS, Kristanti AN, Kuswarini S, Wungu CDK, Soetjipto S, et al. Isolation and identification of a flavonoid compound and in vivo lipidlowering properties of Imperata cylindrica. Biomed Rep 2020;13(5):38. link1

[47] Enmozhi SK, Raja K, Sebastine I, Joseph J. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach. J Biomol Struct Dyn 2021;39(9):3092–8. link1

[48] Zahedipour F, Hosseini SA, Sathyapalan T, Majeed M, Jamialahmadi T, AlRasadi K, et al. Potential effects of curcumin in the treatment of COVID-19 infection. Phytother Res 2020;34(11):2911–20. link1

[49] Du A, Zheng R, Disoma C, Li S, Chen Z, Li S, et al. Epigallocatechin-3-gallate, an active ingredient of traditional Chinese medicines, inhibits the 3CLpro activity of SARS-CoV-2. Int J Biol Macromol 2021;176:1–12. link1

[50] Yu R, Chen L, Lan R, Shen R, Li P. Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. Int J Antimicrob Agents 2020;56(2):106012. link1

[51] Aanouz I, Belhassan A, El-Khatabi K, Lakhlifi T, El-ldrissi M, Bouachrine M. Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: computational investigations. J Biomol Struct Dyn 2021;39(8):2971–9. link1

[52] Wei TZ, Wang H, Wu XQ, Lu Y, Guan SH, Dong FQ, et al. In silico screening of potential spike glycoprotein inhibitors of SARS-CoV-2 with drug repurposing strategy. Chin J Integr Med 2020;26(9):663–9. link1

[53] Nebigil CG, Moog C, Vagner S, Benkirane-Jessel N, Smith DR, Désaubry L. Flavaglines as natural products targeting eIF4A and prohibitins: from traditional Chinese medicine to antiviral activity against coronaviruses. Eur J Med Chem 2020;203:112653. link1

[54] Ting D, Dong N, Fang L, Lu J, Bi J, Xiao S, et al. Multisite inhibitors for enteric coronavirus: antiviral cationic carbon dots based on curcumin. ACS Appl Nano Mater 2018;1(10):5451–9. link1

[55] Wen CC, Kuo YH, Jan JT, Liang PH, Wang SY, Liu HG, et al. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. J Med Chem 2007;50(17):4087–95. link1

[56] Cheng PW, Ng LT, Chiang LC, Lin CC. Antiviral effects of saikosaponins on human coronavirus 229E in vitro. Clin Exp Pharmacol Physiol 2006;33 (7):612–6. link1

[57] Chikhale R, Sinha SK, Wanjari M, Gurav NS, Ayyanar M, Prasad S, et al. Computational assessment of saikosaponins as adjuvant treatment for COVID-19: molecular docking, dynamics, and network pharmacology analysis. Mol Divers 2021;25(3):1889–904. link1

[58] Ho T, Wu S, Chen J, Li C, Hsiang C. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res 2007;74(2):92–101. link1

[59] Ulasli M, Gurses SA, Bayraktar R, Yumrutas O, Oztuzcu S, Igci M, et al. The effects of Nigella sativa (Ns), Anthemis hyalina (Ah) and Citrus sinensis (Cs) extracts on the replication of coronavirus and the expression of TRP genes family. Mol Biol Rep 2014;41(3):1703–11. link1

[60] Kim HY, Shin HS, Park H, Kim YC, Yun YG, Park S, et al. In vitro inhibition of coronavirus replications by the traditionally used medicinal herbal extracts, Cimicifuga rhizoma, Meliae cortex, Coptidis rhizoma, and Phellodendron cortex. J Clin Virol 2008;41(2):122–8. link1

[61] Cui C, Huang C, Zhou W, Ji X, Zhang F, Wang L, et al. AGTR2, one possible novel key gene for the entry of SARS-CoV-2 into human cells. IEEE/ACM Trans Comput Biol Bioinform 2021;18(4):1230–3. link1

[62] Gao K, Song YP, Song A. Exploring active ingredients and function mechanisms of Ephedra-bitter almond for prevention and treatment of corona virus disease 2019 (COVID-19) based on network pharmacology. BioData Min 2020;13(1):19. link1

[63] Lv Y, Wang S, Liang P, Wang Y, Zhang X, Jia Q, et al. Screening and evaluation of anti-SARS-CoV-2 components from Ephedra sinica by ACE2/CMC-HPLC-ITTOF-MS approach. Anal Bioanal Chem 2021;413(11):2995–3004. link1

[64] Li X, Qiu Q, Li M, Lin H, Cao S, Wang Q, et al. Chemical composition and pharmacological mechanism of Ephedra–Glycyrrhiza drug pair against coronavirus disease 2019 (COVID-19). Aging 2021;13(4):4811–30. link1

[65] Cai Y, Zeng M, Chen YZ. The pharmacological mechanism of Huashi Baidu formula for the treatment of COVID-19 by combined network pharmacology and molecular docking. Ann Palliat Med 2021;10(4):3864–95. link1

[66] Zhou YY, Gao WY, Gu XR, Chen ZQ, Zhao HY, Bian BL, et al. Identification and attribution of chemical constituents of Qingfei Paidu decoction based on UHPLC-LTQ-Orbitrap-MS technology. China J Clin Mater Med 2020;45 (13):3035–44. Chinese. link1

[67] Liu W, Ge GB, Wang YL, Huang K, Chen JM, Wang CH, et al. Chemical constituent and tissue distribution study of Qingfei Paidu decoction in mice using UHPLC-Q-Orbitrap HRMS. Chin Tradit Herbal Drugs 2020;51 (8):2035–45. Chinese. link1

[68] Chen J, Wang YK, Gao Y, Hu LS, Yang JW, Wang JR, et al. Protection against COVID-19 injury by Qingfei Paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming. Biomed Pharmacother 2020;129:110281. link1

[69] Zhao J, Tian S, Lu D, Yang J, Zeng H, Zhang F, et al. Systems pharmacological study illustrates the immune regulation, anti-infection, anti-inflammation, and multi-organ protection mechanism of Qing-Fei-Pai-Du decoction in the treatment of COVID-19. Phytomedicine 2021;85:153315. link1

[70] Shi N, Liu B, Liang N, Ma Y, Ge Y, Yi H, et al. Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: a retrospective multicenter cohort study. Pharmacol Res 2020;161:105290. link1

[71] Zhang ZJ, Wu WY, Hou JJ, Zhang LL, Li FF, Gao L, et al. Active constituents and mechanisms of Respiratory Detox Shot, a traditional Chinese medicine prescription, for COVID-19 control and prevention: network-molecular docking-LC-MSE analysis. J Integr Med 2020;18(3):229–41. link1

[72] Li Q, Bai C, Yang R, Xing W, Pang X, Wu S, et al. Deciphering the pharmacological mechanisms of Ma Xing Shi Gan decoction against COVID19 through integrating network pharmacology and experimental exploration. Front Pharmacol 2020;11:581691. link1

[73] Li Y, Chu F, Li P, Johnson N, Li T, Wang Y, et al. Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification. J Ethnopharmacol 2021;271:113854. link1

[74] Ding Y, Zeng L, Li R, Chen Q, Zhou B, Chen Q, et al. The Chinese prescription Lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Altern Med 2017;17(1):130. link1

[75] Zheng S, Baak JP, Li S, Xiao W, Ren H, Yang H, et al. Network pharmacology analysis of the therapeutic mechanisms of the traditional Chinese herbal formula Lian Hua Qing Wen in corona virus disease 2019 (COVID-19), gives fundamental support to the clinical use of LHQW. Phytomedicine 2020;79:153336. link1

[76] Chen X, Wu Y, Chen C, Gu Y, Zhu C, Wang S, et al. Identifying potential antiCOVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening. Acta Pharm Sin B 2021;11(1):222–36. link1

[77] Li R, Hou Y, Huang J, Pan W, Ma Q, Shi Y, et al. Lianhuaqingwen exerts antiviral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 2020;156:104761. link1

[78] Ma Q, Pan W, Li R, Liu B, Li C, Xie Y, et al. Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-jB signaling pathway. Pharmacol Res 2020;158:104850. link1

[79] Pang WT, Jin XY, Pang B, Yang FW, Wang H, Liu CX, et al. Analysis on pattern of prescriptions and syndromes of traditional Chinese medicine for prevention and treatment of COVID-19. China J Clin Mater Med 2020;45 (6):1242–7. Chinese. link1

[80] Li X, Lin H, Wang Q, Cui L, Luo H, Luo L. Chemical composition and pharmacological mechanism of Shenfu decoction in the treatment of novel coronavirus pneumonia (COVID-19). Drug Dev Ind Pharm 2020;46 (12):1947–59. link1

[81] Deng W, Xu Y, Kong Q, Xue J, Yu P, Liu J, et al. Therapeutic efficacy of Pudilan Xiaoyan oral liquid (PDL) for COVID-19 in vitro and in vivo. Signal Transduct Target Ther 2020;5(1):66. link1

[82] Zheng Y, Liu Z, Zhu XQ, Wang BL. To Investigation of the mechanism of Xuebijing injection in COVID-19 treatment based on network pharmacology and molecular docking. Chin J Comp Med 2020;30(7):57–64. Chinese. link1

[83] Thompson DA, Cormier EG, Dragic T. CCR5 and CXCR4 usage by non-clade B human immunodeficiency virus type 1 primary isolates. J Virol 2002;76 (6):3059–64. link1

[84] Lindahl JF, Grace D. The consequences of human actions on risks for infectious diseases: a review. Infect Ecol Epidemiol 2015;5(1):30048. link1

[85] Moscona A. Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. J Clin Invest 2005;115(7):1688–98. link1

[86] Zhao J, Wohlford-Lenane C, Zhao J, Fleming E, Lane TE, McCray Jr PB, et al. Intranasal treatment with poly(I●C) protects aged mice from lethal respiratory virus infections. J Virol 2012;86(21):11416–24. link1

[87] Kumaki Y, Salazar AM, Wandersee MK, Barnard DL. Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol (Poly IC:LC), in a lethal SARS-CoV-infected BALB/c mouse model. Antiviral Res 2017;139:1–12. link1

[88] Jasso-Miranda C, Herrera-Camacho I, Flores-Mendoza LK, Dominguez F, Vallejo-Ruiz V, Sanchez-Burgos GG, et al. Antiviral and immunomodulatory effects of polyphenols on macrophages infected with dengue virus serotypes 2 and 3 enhanced or not with antibodies. Infect Drug Resist 2019;12:1833–52. link1

[89] Mounce BC, Cesaro T, Carrau L, Vallet T, Vignuzzi M. Curcumin inhibits Zika and chikungunya virus infection by inhibiting cell binding. Antiviral Res 2017;142:148–57. link1

[90] Sordillo PP, Helson L. Curcumin suppression of cytokine release and cytokine storm. A potential therapy for patients with Ebola and other severe viral infections. In Vivo 2015;29(1):1–4. link1

[91] Wang YX, Ma JR, Wang SQ, Zeng YQ, Zhou CY, Ru YH, et al. Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan decoction in treating COVID-19. Eur Rev Med Pharmacol Sci 2020;24(6):3360–84. link1

[92] Zhao J, Yang X, Wang C, Song S, Cao K, Wei T, et al. Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-CoV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a. Biomed Pharmacother 2020;129:110436. link1

[93] Kao SJ, Su CF, Liu DD, Chen HI. Endotoxin-induced acute lung injury and organ dysfunction are attenuated by pentobarbital anaesthesia. Clin Exp Pharmacol Physiol 2007;34(5–6):480–7. link1

[94] Johnson ER, Matthay MA. Acute lung injury: epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv 2010;23(4):243–52. link1

[95] Standiford TJ, Ward PA. Therapeutic targeting of acute lung injury and acute respiratory distress syndrome. Transl Res 2016;167(1):183–91. link1

[96] Weng TI, Wu HY, Kuo CW, Liu SH. Honokiol rescues sepsis-associated acute lung injury and lethality via the inhibition of oxidative stress and inflammation. Intensive Care Med 2011;37(3):533–41. link1

[97] Shin NR, Shin IS, Song HH, Hong JM, Kwon OK, Jeon CM, et al. Callicarpa japonica Thunb. reduces inflammatory responses: a mouse model of lipopolysaccharide-induced acute lung injury. Int Immunopharmacol 2015;26(1):174–80. link1

[98] Koksel O, Ozdulger A, Tamer L, Cinel L, Ercil M, Degirmenci U, et al. Effects of caffeic acid phenethyl ester on lipopolysaccharide-induced lung injury in rats. Pulm Pharmacol Ther 2006;19(2):90–5. link1

[99] Yang W, Qiang D, Zhang M, Ma L, Zhang Y, Qing C, et al. Isoforskolin pretreatment attenuates lipopolysaccharide-induced acute lung injury in animal models. Int Immunopharmacol 2011;11(6):683–92. link1

[100] Sun Q, Chen L, Gao M, Jiang W, Shao F, Li J, et al. Ruscogenin inhibits lipopolysaccharide-induced acute lung injury in mice: involvement of tissue factor, inducible NO synthase and nuclear factor (NF)-jB. Int Immunopharmacol 2012;12(1):88–93. link1

[101] Patel VJ, Biswas Roy S, Mehta HJ, Joo M, Sadikot RT. Alternative and natural therapies for acute lung injury and acute respiratory distress syndrome. BioMed Res Int 2018;2018:1–9. link1

[102] Cui Y, Xin H, Tao Y, Mei L, Wang Z. Arenaria kansuensis attenuates pulmonary fibrosis in mice via the activation of Nrf2 pathway and the inhibition of NFjB/TGF-b1/Smad2/3 pathway. Phytother Res 2021;35(2):974–86. link1

[103] Liu Z, Wang P, Lu S, Guo R, Gao W, Tong H, et al. Liquiritin, a novel inhibitor of TRPV1 and TRPA1, protects against LPS-induced acute lung injury. Cell Calcium 2020;88:102198. link1

[104] Li X, Shan C, Wu Z, Yu H, Yang A, Tan B. Emodin alleviated pulmonary inflammation in rats with LPS-induced acute lung injury through inhibiting the mTOR/HIF-1a/VEGF signaling pathway. Inflamm Res 2020;69 (4):365–73. link1

[105] Gao Z, Sui J, Fan R, Qu W, Dong X, Sun D. Emodin protects against acute pancreatitis-associated lung injury by inhibiting NLPR3 inflammasome activation via Nrf2/HO-1 signaling. Drug Des Devel Ther 2020;14:1971–82. link1

[106] Yin JT, Wan B, Liu DD, Wan SX, Fu HY, Wan Y, et al. Emodin alleviates lung injury in rats with sepsis. J Surg Res 2016;202(2):308–14. link1

[107] Tsai CL, Lin YC, Wang HM, Chou TC. Baicalein, an active component of Scutellaria baicalensis, protects against lipopolysaccharide-induced acute lung injury in rats. J Ethnopharmacol 2014;153(1):197–206. link1

[108] Chen YQ, Chai YS, Xie K, Yu F, Wang CJ, Lin SH, et al. Curcumin promotes the expression of IL-35 by regulating regulatory T cell differentiation and restrains uncontrolled inflammation and lung injury in mice. Inflammation 2020;43(5):1913–24. link1

[109] Liu Q, Ci X, Wen Z, Peng L. Diosmetin alleviates lipopolysaccharide-induced acute lung injury through activating the Nrf2 pathway and inhibiting the NLRP3 inflammasome. Biomol Ther 2018;26(2):157–66. link1

[110] Wang YM, Ji R, Chen WW, Huang SW, Zheng YJ, Yang ZT, et al. Paclitaxel alleviated sepsis-induced acute lung injury by activating MUC1 and suppressing TLR-4/NF-jB pathway. Drug Des Devel Ther 2019;13:3391–404. link1

[111] Zhou BX, Li J, Liang XL, Pan XP, Hao YB, Xie PF, et al. b-sitosterol ameliorates influenza A virus-induced proinflammatory response and acute lung injury in mice by disrupting the cross-talk between RIG-I and IFN/STAT signaling. Acta Pharmacol Sin 2020;41(9):1178–96. link1

[112] Zhang Y, Zhang B, Xu DQ, Li WP, Xu M, Li JH, et al. Tanshinone IIA attenuates seawater aspiration-induced lung injury by inhibiting macrophage migration inhibitory factor. Biol Pharm Bull 2011;34(7):1052–7. link1

[113] Fu S, Lu W, Yu W, Hu J. Protective effect of Cordyceps sinensis extract on lipopolysaccharide-induced acute lung injury in mice. Biosci Rep 2019;39(6): BSR20190789.

[114] Chen X, Han W, Wang G, Zhao X. Application prospect of polysaccharides in the development of anti-novel coronavirus drugs and vaccines. Int J Biol Macromol 2020;164:331–43. link1

[115] Chen RR, Li YJ, Chen JJ, Lu CL. A review for natural polysaccharides with antipulmonary fibrosis properties, which may benefit to patients infected by 2019-nCoV. Carbohydr Polym 2020;247:116740. link1

[116] Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 2018;9 (2):e00221-e18. link1

[117] Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 2020;248:117477. link1

[118] Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, et al. Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically Ill patients with influenza virus infection. J Infect Dis 2020;221(10):1688–98.

[119] Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect 2020;53(3):436–43. link1

[120] Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov 2016;15(5):327–47. link1

[121] Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 2020;55 (5):105954. link1

[122] Jin X, Pang B, Zhang J, Liu Q, Yang Z, Feng J, et al. Core outcome set for clinical trials on coronavirus disease 2019 (COS-COVID). Engineering 2020;6 (10):1147–52. link1

[123] Zhang F, Huang J, Liu W, Wang CR, Liu YF, Tu DZ, et al. Inhibition of drugmetabolizing enzymes by Qingfei Paidu decoction: implication of herb-drug interactions in COVID-19 pharmacotherapy. Food Chem Toxicol 2021;149:111998. link1

[124] Yu S, Zhu Y, Xu J, Yao G, Zhang P, Wang M, et al. Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2. Phytomedicine 2021;85:153364. link1

[125] Wei WL, Wu SF, Li HJ, Li ZW, Qu H, Yao CL, et al. Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/ MS. Chin J Nat Med 2021;19(6):473–80. link1

[126] Wu GS, Zhong J, Zheng NN, Wang CR, Jin HL, Ge GB, et al. Investigation of modulating effect of Qingfei Paidu decoction on host metabolism and gut microbiome in rats. China J Clin Mater Med 2020;45(15):3726–39. Chinese. link1

[127] Yang R, Liu H, Bai C, Wang Y, Zhang X, Guo R, et al. Chemical composition and pharmacological mechanism of Qingfei Paidu decoction and Ma Xing Shi Gan decoction against coronavirus disease 2019 (COVID-19): in silico and experimental study. Pharmacol Res 2020;157:104820. link1

[128] Utomo R, Ikawati M, Meiyanto E. Revealing the potency of citrus and galangal constituents to halt SARS-CoV-2 infection. Preprint 2020.

[129] Tu P, Tian R, Lu Y, Zhang Y, Zhu H, Ling L, et al. Beneficial effect of Indigo Naturalis on acute lung injury induced by influenza A virus. Chin Med 2020;15(1):128. link1

[130] Zhang X, Gao R, Zhou Z, Tang X, Lin J, Wang L, et al. A network pharmacology based approach for predicting active ingredients and potential mechanism of Lianhuaqingwen capsule in treating COVID-19. Int J Med Sci 2021;18 (8):1866–76. link1

[131] Xia QD, Xun Y, Lu JL, Lu YC, Yang YY, Zhou P, et al. Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID-19. Cell Prolif 2020;53(12): e12949. link1

[132] Zheng WJ, Yan Q, Ni YS, Zhan SF, Yang LL, Zhuang Hf, et al. Examining the effector mechanisms of Xuebijing injection on COVID-19 based on network pharmacology. BioData Min 2020;13(1):17. link1

[133] Wang Y, Ru Y, Zhuo G, Sheng M, Wang S, Ma J, et al. Investigation of the potential mechanism governing the effect of the Shen Zhu San on COVID-19 by network pharmacology. Evid Based Complement Alternat Med 2020;2020:1–23. link1

[134] Ye M, Luo G, Ye D, She M, Sun N, Lu YJ, et al. Network pharmacology, molecular docking integrated surface plasmon resonance technology reveals the mechanism of Toujie Quwen granules against coronavirus disease 2019 pneumonia. Phytomedicine 2021;85:153401. link1